UPDATE: Amgen Spiking Lower 1.5%, Says Primary Endpoint of Durable Response Rate Met in Phase 3 Study of Talimogene, Secondary Endpoint Not Met

Amgen (NASDAQ: AMGN) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, ...